Enoxaparin (Lovenox) Dosing for DVT Prophylaxis
For standard DVT prophylaxis in most hospitalized adults, use enoxaparin 40 mg subcutaneously once daily. This is the most widely recommended dose across multiple clinical settings including medical patients, surgical patients, and cancer patients 1, 2, 3.
Standard Dosing by Clinical Setting
Medical Patients (Hospitalized)
- 40 mg SC once daily for the duration of hospital stay or until fully ambulatory 1, 2
- Continue for at least 7-14 days depending on mobility status
Surgical Patients
- 40 mg SC once daily starting 2-4 hours preoperatively OR 10-12 hours preoperatively, then continuing daily 1, 2
- Alternative: 30 mg SC every 12 hours (particularly for hip replacement surgery) 3, 4
- Continue for at least 7-10 days; consider extending to 4 weeks for high-risk surgical patients 1, 2
Cancer Patients (Outpatient)
- 40 mg SC once daily for ambulatory cancer patients at high risk 1
- Duration somewhat uncertain; most studies evaluated up to 6 months 1
Critical Dose Adjustments
Severe Renal Impairment (CrCl <30 mL/min)
Reduce to 30 mg SC once daily 5, 3. This is the only FDA-approved dose adjustment and is supported by evidence showing 2-3 fold increased bleeding risk with standard doses in severe renal impairment 5.
For moderate renal impairment (CrCl 30-50 mL/min), evidence suggests increased bleeding risk exists but no formal dose reduction is FDA-approved 5. Consider closer monitoring or using unfractionated heparin in this population 5.
Important caveat: Enoxaparin is the only LMWH with established renal dosing. Dalteparin may be safer in renal impairment as it shows less accumulation 5.
Obesity (BMI ≥40 kg/m² or Weight >120 kg)
Increase to 40 mg SC twice daily for prophylaxis 6, 7, 8. Standard once-daily dosing is insufficient in morbidly obese patients, with studies showing subtherapeutic anti-Xa levels 7, 8.
Alternative weight-based approach: 0.5 mg/kg SC twice daily for prophylaxis in obesity class ≥2 7. For patients >100 kg, some institutions use fixed higher doses rather than weight-based dosing to avoid excessive doses 7.
Low Body Weight (<50-57 kg or BMI <18.5 kg/m²)
Reduce to 30 mg SC once daily 9, 10. Standard 40 mg dosing in underweight patients results in higher anti-Xa levels and increased bleeding risk 9, 10. A recent 2025 study showed no difference in VTE rates but numerically lower bleeding with reduced dosing 9.
Critical consideration: Underweight colorectal surgery patients had 7% bleeding events with standard dosing versus 0% with reduced dosing 10.
Elderly Patients (≥75 years)
Use standard dosing (40 mg once daily) but monitor closely for bleeding 5, 3. Age >75 years is independently associated with increased bleeding risk 11.
High Bleeding Risk Patients
When anticoagulation is not contraindicated but bleeding risk is elevated:
- Fondaparinux 2.5 mg SC once daily is preferred over enoxaparin 2
- If enoxaparin must be used, consider 30 mg once daily with close monitoring
- Mechanical prophylaxis should be added in all cases
Special Populations
Post-Bariatric Surgery
40 mg SC twice daily for class 3 obesity (BMI ≥40 kg/m²) 7. Standard dosing is inadequate, though evidence for augmented dosing shows uncertain benefit with possible increased bleeding 7.
Pregnancy
Standard weight-based dosing often results in subtherapeutic levels 12. Consider anti-Xa monitoring if available, targeting prophylactic range 0.2-0.4 IU/mL 12.
Cancer Patients with Renal Impairment
For CrCl <30 mL/min, use 30 mg SC once daily 5. Consider monitoring peak anti-Xa levels (target 0.5-1.5 IU/mL for treatment doses) if using dalteparin instead 5.
Common Pitfalls to Avoid
Do not switch between LMWHs and unfractionated heparin during treatment—this increases bleeding risk 13
Do not use standard dosing in severe renal impairment—enoxaparin accumulates significantly with CrCl <30 mL/min 5, 14
Do not underdose obese patients—standard 40 mg once daily is insufficient for BMI ≥40 kg/m² 7, 8
Do not assume all LMWHs behave identically in renal failure—only enoxaparin has validated renal dosing 5
Avoid tinzaparin in elderly patients (≥70 years) with renal insufficiency—increased mortality was observed in this population 5
When to Consider Anti-Xa Monitoring
Routine monitoring is not recommended for standard prophylaxis 12. Consider monitoring only in:
- Extremes of body weight (<50 kg or >120 kg) with recurrent VTE or bleeding
- Severe renal impairment (CrCl <30 mL/min) if bleeding occurs
- Pregnancy with prior VTE
- Mechanical heart valves (though enoxaparin is not adequately studied in this population) 3
Target prophylactic anti-Xa range: 0.2-0.4 IU/mL (measured 4 hours post-dose) 15, 12